Our regulatory team acknowledges the fact that complete and enhanced understanding of international regulatory requirements is the most significant of the pre requisites of this business.
The team builds up formulations for generic products in total synchronization with the most rigorous regulatory necessities. Formulation studies, method development and validation, study on container closure systems and stability studies are conducted in line with international guidelines.
The potential of regulatory team emanates from skilled and committed manpower for various fields that involve Regulated and non-Regulated markets, Intellectual Property Rights (IPR), and Clinical Trial Studies. It also prepares final reports and statistical analysis of Data.
The clinical trial team is mainly responsible for formulation of protocols along with ICH guidelines, selection of study centers, regulatory procedures and approvals from government entities and identification.
Our idea of getting associated and marketing of branded formulations enables the organization with insignificant chores, assured business and distributed marketing expenditure for the business generated.
The company’s commitment to reasearch and development is unquestionanble. Abaris largely focuses on advancement and development of novel products and drug delivery system for the treatment of acute illness. Our research and development team is consistently working on the various technologies.
The R & D team at Abaris is well supported by qualified scientists who have earned qualitative experience in the sphere of pharmaceutical sciences and allied areas, networks. They are also linked with the global scientific community along with various other companies, universities and scientists with similar interest areas.
Plastic containers manufactured without human touch.
Abaris healthcare’s newly launched products include Montello, for the treatment of seasonal allergic rhinitis and asthma and water for injection 5ml & 10ml.
